Sable, a portfolio company of Turret Capital, announces its pre-seed funding and launch
NEW YORK, Jan. 15, 2026 /PRNewswire/ — Turret Capital, a leading healthcare-focused venture firm, today announced the launch of Sable, a pioneering biotech driven consumer beauty company. Backed by pre-seed investment from Turret Capital and SOSV, Sable debuts with a mission to disrupt the body care and beauty market through advanced topical solutions. By leveraging proprietary biotech innovations, Sable addresses the aesthetic needs of the modern consumer, offering high-performance products designed to visibly improve body contours and skin vitality.
Sable’s core offering is built upon breakthrough scientific discoveries at Columbia University Medical Center. Developed by a team of world-class scientists, preclinical research studies demonstrated that a novel ingredient could be selectively taken up by fat cells and achieve up to 70% reduction in fat cell volume. Inspired by these findings, Sable is further developing this exclusively licensed asset into an advanced topical formulation of body creams.
Addressing the New Era of Body Aesthetics and Longevity
As consumer interest in body-sculpting procedures and wellness-led lifestyle changes (such as GLP-1 medications) continues to surge, Sable fills a critical gap in the prestige beauty market. The product line is specifically formulated to address:
- Targeted Aesthetic Contouring: Offering a topical solution for individuals seeking to enhance the visual definition of specific areas with stubborn concerns.
- Aesthetic Maintenance: Supporting the consumer’s needs for those undergoing significant lifestyle or wellness transitions, helping to “future-proof” and “fine tune” aesthetic results.
- Post-Treatment Complement: Helping to sustain and optimize the visual enhancement of the body following professional aesthetic services.
Source link
Leave a Reply